Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer
58
Zitationen
20
Autoren
2024
Jahr
Abstract
Multi-modal image analysis using deep learning (DL) lays the foundation for neoadjuvant treatment (NAT) response monitoring. However, existing methods prioritize extracting multi-modal features to enhance predictive performance, with limited consideration on real-world clinical applicability, particularly in longitudinal NAT scenarios with multi-modal data. Here, we propose the Multi-modal Response Prediction (MRP) system, designed to mimic real-world physician assessments of NAT responses in breast cancer. To enhance feasibility, MRP integrates cross-modal knowledge mining and temporal information embedding strategy to handle missing modalities and remain less affected by different NAT settings. We validated MRP through multi-center studies and multinational reader studies. MRP exhibited comparable robustness to breast radiologists, outperforming humans in predicting pathological complete response in the Pre-NAT phase (ΔAUROC 14% and 10% on in-house and external datasets, respectively). Furthermore, we assessed MRP's clinical utility impact on treatment decision-making. MRP may have profound implications for enrolment into NAT trials and determining surgery extensiveness.
Ähnliche Arbeiten
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
2000 · 15.699 Zit.
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 · 13.213 Zit.
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 · 11.469 Zit.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 · 10.905 Zit.
Gene expression profiling predicts clinical outcome of breast cancer
2002 · 9.587 Zit.
Autoren
Institutionen
- Radboud University Nijmegen(NL)
- Maastricht University Medical Centre(NL)
- Radboud University Medical Center(NL)
- The Netherlands Cancer Institute(NL)
- St. Joseph’s Healthcare Hamilton(CA)
- Fujian Medical University(CN)
- Fujian Provincial Hospital(CN)
- Fuzhou University(CN)
- Kunming Medical University(CN)
- Cork University Hospital(IE)
- Harvard University(US)
- Jinan University(CN)
- Agostino Gemelli University Polyclinic(IT)
- Istituti di Ricovero e Cura a Carattere Scientifico(IT)
- Key Laboratory of Guangdong Province(CN)
- Guangdong Academy of Medical Sciences(CN)
- Guangdong Provincial People's Hospital(CN)
- Southern Medical University(CN)
- Macao Polytechnic University(MO)